In conclusion, the present study characterizes the capacity of the human Gal3 lectin to bind non-classical anti-cancer compounds [42], in particular Au3+TPPS that appears to be an appropriate alternative to classical anti-cancer compounds [52,53,54,55,56], and reveals new perspectives in the drug delivery of anti-cancer agents [62]. The gene discussed is LGALS3; the disease is cancer.